<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03831698</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-2018-Omega3-CRC-Prev</org_study_id>
    <nct_id>NCT03831698</nct_id>
  </id_info>
  <brief_title>Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)</brief_title>
  <official_title>Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study aimed at assessing the effects of moderate dose omega-3-acid ethyl
      esters capsules (generic Lovaza) on molecular, and intestinal microbiota changes in
      participants at high risk for colorectal cancer. The study will be a single arm, open label
      study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention rate of participants</measure>
    <time_frame>12 months</time_frame>
    <description>Feasibility is defined as at least 80% retention rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with treatment-related adverse events in each arm.</measure>
    <time_frame>12 months</time_frame>
    <description>Measured by Common Terminology Criteria Adverse Events (CTCAE) V5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Lynch Syndrome</condition>
  <arm_group>
    <arm_group_label>Omega-3, 2 grams</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega-3 fatty acid ethyl esters (2 grams) orally (by mouth) once per day for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acid ethyl esters (2 gram)</intervention_name>
    <description>Omega-3 fatty acid ethyl esters (2 gram)</description>
    <arm_group_label>Omega-3, 2 grams</arm_group_label>
    <other_name>lovaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability of participant or Legally Authorized Representative (LAR) to understand this
             study, and participant or LAR willingness to sign a written informed consent

          -  Candidate for elective endoscopy procedure

          -  Participants with known Lynch Syndrome

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

          -  Willing to undergo a colonoscopy and biopsy at baseline and another colonoscopy and
             biopsy at 12 months visit.

          -  Participants taking Aspirin for chemoprevention must agree to stop it for at least 4
             weeks prior to study entry and throughout the trial period

          -  Adequate organ and marrow function

          -  Women of child-bearing potential and men with partners of child-bearing potential must
             agree to practice sexual abstinence, or to use two forms of adequate contraception
             (hormonal AND barrier method of birth control) prior to study entry, for the duration
             of study participation, and for 90 days following completion of therapy. If a woman
             becomes pregnant or suspects she is pregnant while participating in this study, she
             should inform her treating physician immediately.

          -  Men of child-bearing potential must not father a child or donate sperm while on this
             study and for 90 days after their last study treatment.

        Exclusion Criteria:

          -  Current or anticipated use of other investigational agents while participating in this
             study.

          -  Psychiatric illness/social situations that could limit compliance with study
             requirements.

          -  Pregnant or breast feeding.

          -  Familial adenomatous polyposis, Putz-Jeghers disease, ulcerative colitis, or Crohn's
             disease.

          -  Previous or known active malignancies, except non-melanoma skin cancers, unless
             curatively treated and with no evidence of recurrence for more than 5 years

          -  Current use of anticoagulation therapy

          -  Current use of therapeutic doses of aspirin for reasons other than chemoprevention

          -  Use of omega 3 fatty acids or flaxseed supplements within 4 weeks before this study's
             screening/baseline colonoscopy

          -  Use of high dose omega 3 fatty acids within the past 3 months prior to study
             baseline/screening

          -  Current, regular use of non-steroidal anti-inflammatory drugs (NSAIDS)

          -  Allergy to fish and/or fish products

          -  Uncontrolled infectious disease

          -  Malabsorption syndrome, disease affecting gastrointestinal function, or previous
             resection of the stomach or small bowel.

          -  Unable to swallow and retain oral medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anwaar Saeed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Kansas Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CT Nurse Navigator</last_name>
    <phone>913-945-7552</phone>
    <email>ctnursenav@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center, Westwood Campus</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Nurse Navigator</last_name>
      <phone>913-945-7552</phone>
      <email>ctnursenav@kumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 4, 2019</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Omega 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

